AbbVie Sees Consensus Earnings Raised to $14.49, Shares Up 8% in Four Weeks
AbbVie holds a Zacks Rank #3 with a VGM Score of B and Momentum Style Score of A, as shares rose 8% over the past four weeks. For fiscal 2026, seven analysts raised earnings estimates, lifting the consensus to $14.49 per share with a 3.2% average surprise.
1. Zacks Rank and Style Scores
AbbVie currently holds a Zacks Rank #3 (Hold), combined with a VGM Score of B and a Momentum Style Score of A, indicating strong price and earnings estimate trends relative to value and growth metrics.
2. Recent Price Momentum
Shares of AbbVie have climbed 8% over the past four weeks, reflecting heightened investor interest driven by positive momentum indicators and favorable market sentiment within the pharmaceutical sector.
3. Analyst Estimate Revisions
In the past 60 days, seven analysts raised their fiscal 2026 earnings forecasts for AbbVie, boosting the Zacks Consensus Estimate by $0.07 to $14.49 per share, against an average earnings surprise of 3.2%.
4. Growth Drivers
AbbVie’s long-term growth is supported by its 2020 $63 billion acquisition of Allergan and new immunology treatments Skyrizi and Rinvoq, which are reducing reliance on Humira post-patent expiry.